4.3 Article

Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease

Journal

JOURNAL OF NEURAL TRANSMISSION
Volume 116, Issue 10, Pages 1289-1293

Publisher

SPRINGER WIEN
DOI: 10.1007/s00702-009-0273-2

Keywords

Parkinson's disease; Mortalin; Mutations; Genetic risk

Funding

  1. Asociacion Parkinson Asturias
  2. Obra Social CAJASTUR
  3. FICYT-Principado de Asturias
  4. Spanish Fondo de Investigaciones Sanitarias-Fondos FEDER European Union [FIS 05/08, 08/0915]

Ask authors/readers for more resources

Mortalin is a mitochondrial chaperone of the heat shock protein 70 family. Mortalin plays a central role in mitochondrial biogenesis through its capacity to direct the import of nuclear-encoded proteins into the mitochondria. As mitochondrial dysfunction has been involved in Parkinson's disease (PD), changes in mortalin function and expression could manifest as a higher risk of developing PD. In agreement with this, mortalin expression was decreased in the mitochondrial fraction of neurons from the substantia nigra of PD patients. We hypothesised that DNA variants in the mortalin gene (HSPA9) could contribute to the risk of developing PD. We analysed the 17 HSPA9 coding exons in 330 PD patients and 250 controls. In addition to several polymorphisms, found in patients and controls, three variants were found in 3 patients but none of the controls: two missense (R126 > W and P509 > S) and a 17 bp insertion in intron 8 (predicted to affect RNA splicing). Our study suggests that putative mutations in the mortalin, although rare, could contribute to the risk of developing PD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available